局部晚期非小细胞肺癌同步放化疗不同方案的比较与量化:临床结果及扩展LQ与TCP模型的理论结果
回顾性分析151例局部晚期非小细胞肺癌患者,按同步化疗方案分为5组(单纯放疗24例、4周EP 30例、3周AP 26例、周疗TP 37例、周疗DP 34例),比较野内无局部区域进展生存(LPFS)与毒性,并建立LQRGC/TCP模型量化化疗所致生物有效剂量。中位随访54.5个月,周疗DP与4周EP组野内LPFS较好(EP 46.2个月 vs AP 30.3个月 vs TP 12.2个月 vs DP未达到 vs 单纯放疗12.2个月,p=0.001),4周EP组≥3级白细胞减少发生率高于其他四组(EP 76.7% vs AP 15.4% vs TP 24.3% vs DP 14.7% vs 单纯放疗12.5%,p<0.001)。
要点
- 周疗DP与4周EP组野内LPFS优于AP、TP及单纯放疗组。
- 4周EP组≥3级白细胞减少发生率高于其他四组。
- LQRGC/TCP模型拟合野内LPFS的平均绝对误差6.36%、相对误差12.12%。
核心结论
- LQRGC/TCP模型对野内LPFS拟合精度较好。
- 经模型量化,4周EP与周疗DP同步放疗时化疗所致生物有效剂量较高。
研究设计与样本
- 回顾性分析151例局部晚期非小细胞肺癌患者,按同步化疗方案分为5组:单纯放疗24例、4周EP 30例、3周AP 26例、周疗TP 37例、周疗DP 34例。
- 比较各组野内LPFS与毒性,并建立整合放射生物学4R、Gompertzian肿瘤生长及化疗效应的LQRGC/TCP模型。
主要发现
- 中位随访54.5个月,各组中位野内LPFS:EP 46.2个月、AP 30.3个月、TP 12.2个月、DP未达到、单纯放疗12.2个月,p=0.001。
- ≥3级白细胞减少发生率:EP 76.7%、AP 15.4%、TP 24.3%、DP 14.7%、单纯放疗12.5%,p<0.001,4周EP组高于其他四组。
- LQRGC/TCP模型拟合野内LPFS的平均绝对误差6.36%、平均相对误差12.12%。
- 化疗所致生物有效剂量:EP 5.17 Gy、AP 0.63 Gy、TP 1.89 Gy、DP 2.52 Gy。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To develop a new radiobiological model and compare the efficacy of four concurrent chemotherapy regimens administered with radiotherapy in locally advanced non-small-cell lung cancer (LANSCLC) by in-field locoregional progression-free survival (LPFS). MATERIALS AND METHODS: 151 LANSCLC patients were reviewed and divided into 5 groups according to their concurrent chemotherapy regimens, including 24 patients treated with radiotherapy alone, 30 treated with concurrent 4-week etoposide-cisplatin (EP), 26 with 3-week pemetrexed-cisplatin (AP), 37 with weekly paclitaxel-cisplatin (TP) and 34 with weekly docetaxel-cisplatin (DP). In-field LPFS and toxicities were compared among groups. A novel tumor control probability (TCP) model, LQRGC, incorporating four "R"s of radiobiology, Gompertzian tumor growth and chemotherapeutic effect, was related to in-field LPFS. Chemo-induced biologically effective doses (BEDs) in LQRGC/TCP model were used to quantify the concurrent chemotherapeutic efficacy. RESULTS: The median follow-up time was 54.5 months. The weekly DP and 4-week EP groups had favorable median in-field LPFS (EP:46.2 months, AP:30.3 months, TP:12.2 months, DP: not reached, radiotherapy alone: 12.2 months, p = 0.001). The 4-week EP group had a higher incidence of ≥grade 3 leukopenia (EP:76.7%, AP:15.4%, TP:24.3%, DP:14.7%, radiotherapy alone: 12.5%, p < 0.001) than the other four. The LQRGC/TCP model fitted well with the in-field LPFS with the average absolute and relative fitting errors of 6.36% and 12.12%. The chemo-induced BEDs of EP, AP, TP and DP were 5.17, 0.63, 1.89 and 2.52 Gy, respectively. CONCLUSION: The LQRGC/TCP model achieved promising fitting accuracy for in-field LPFS. As quantified by the model, the 4-week EP and weekly DP showed higher chemo-induced BEDs when concurrently administered with radiotherapy in LANSCLC.
引用
- Ai X, Qiu B, Zhou Y, et al. Comparison and quantification of different concurrent chemotherapy regimens with radiotherapy in locally advanced non-small cell lung cancer: Clinical outcomes and theoretical results from an extended LQ and TCP model. Radiother Oncol. 2021. PMID: 34890734. doi:10.1016/j.radonc.2021.11.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。